1. Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors. 2008; 32(1-4):119-28. PubMed PMID: 19096107
2. Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, Sireci A, Wille EJ, Beal MF. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem. 2008 Mar;104(6):1613-21. Epub 2007 Oct 31. PubMed PMID: 17973981.
3. Wada H, Goto H, Hagiwara S, Yamamoto Y. Redox status of coenzyme Q10 is associated with chronological age. J Am Geriatr Soc. 2007 Jul;55(7):1141-2. PubMed PMID: 17608895.
4. Canadian government health agency/ Health Canada, COENZYME Q10 (UBIQUINONE10) Monograph, November 22, 2007. (url: http://www.hc- sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_coenz-Q-10-eng.php)
5. Etsuo Niki, “Biomedical and Clinical Aspects of Coenzyme Q10,” Molecular Aspects of Medicine, Volume 18, Supplement 1, 1997, Pages 63-70 6. Ernster, L; Dallner, G (1995). “Biochemical, physiological and medical aspects of ubiquinone function”. Biochimica et Biophysica Acta 1271 (1):195–204.PMID7599208
7. http://www.numedica.com/literature/Folkers%201993.pdf
8. Giovanni Ravaglia, Paola Forti, Fabiola Maioli, et al., “Effect of micronutrient status on natural killer cell immune function in healthy free-living subjects aged ≥90,” American Journal of Clinical Nutrition, Vol. 71, No. 2, 590-598, February 2000
9. http://www.mbschachter.com/coenzyme_Q-10.htm 10. Ghirlanda, G; Oradei, A; Manto, A; Lippa, S; Uccioli, L; Caputo, S; Greco, AV; Littarru, GP (1993). “Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study”. Journal of clinical pharmacology 33 (3): 226–9. PMID 8463436 11. Majeed, M. Use of piperine as a bioavailability enhancer. US Patent 5744161, October 26, 1999